肿瘤坏死因子（TNF）相关的凋亡诱导配体（TRAIL）在癌症治疗中显示出有希望的治疗潜力，因为它能够通过与同源死亡受体结合来触发外源性凋亡途径，在癌细胞中引起广谱凋亡，而毒性可忽略不计对正常细胞。然而，大多数癌症对 TRAIL 表现出耐药性，限制了其临床应用。克服 TRAIL 疗法的耐药性仍然是制定有效抗癌策略的一个挑战。为了解决 TRAIL 疗法的局限性，一种可行的替代方法是将 TRAIL 与比单一疗法更有效的药物结合起来。这种组合策略旨在诱导协同效应或使耐药癌细胞变得敏感。本综述概述了 TRAIL 联合治疗的相关方式，重点介绍了不同的药物类别。研究结果表明，将 TRAIL 与其他药物联合使用可以有效抵消 TRAIL 疗法在癌症中观察到的耐药性。这些发现为基于 TRAIL 的治疗各种癌症的疗法的未来发展奠定了基础。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) shows promising therapeutic potential in cancer treatment as it is able to trigger extrinsic apoptotic pathways by binding to the cognate death receptor, causing broad-spectrum apoptosis in cancer cells with negligible toxicity to normal cells. However, the majority of cancers display resistance to TRAIL, limiting its clinical utility. Overcoming resistance to TRAIL therapies remains a challenge in the development of effective anti-cancer strategies. To address the limitations of TRAIL therapy, a viable alternative approach involves combining TRAIL with more potent drugs compared to monotherapy. This combination strategy aims to induce synergistic effects or sensitize drug-resistant cancer cells. This review provides an overview of relevant modalities of TRAIL combination therapy, highlighting different drug classes. The findings demonstrate that combining TRAIL with other agents can effectively counteract resistance observed with TRAIL therapies in cancer. These findings lay a foundation for future advancements in TRAIL-based therapies for treating various cancers.Copyright © 2024 Elsevier B.V. All rights reserved.